Trade

with

Versartis Inc
(NASDAQ: VSAR)
AdChoices
20.60
+0.44
+2.18%
After Hours :
20.60
0.00
0.00%

Open

20.34

Previous Close

20.16

Volume (Avg)

66.25k (71.26k)

Day's Range

20.24-21.06

52Wk Range

16.15-36.86

Market Cap.

498.41M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

24.19M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -18.50M

    • Market Cap.

    • 498.41M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -8.73

    • Price/Sales

    • -

    • Price/Book Value

    • 2.58

    • Price/Cash flow

    • -12.63

      • EBITDA

      • -18.35M

      • Return on Capital %

      • -32.42

      • Return on Equity %

      • -33.29

      • Return on Assets %

      • -32.42

      • Book Value/Share

      • 8.00

      • Shares Outstanding

      • 24.19M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 45.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -2.34

        • Cashflow Estimate

        • -2.22

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 38.15

              • 1.52

              • Quick Ratio

              • 37.16

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.03

              • 1.91

              • Book Value/Share

              • 8.00

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.37

                • 61.73

                • P/E Ratio 5-Year High

                • -9.39

                • 237.47

                • P/E Ratio 5-Year Low

                • -4.11

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.49

                • Price/Book Value

                • 2.64

                • 3.26

                • Price/Cash Flow Ratio

                • -12.63

                • 20.88

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -33.29

                    (-)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -32.42

                    (-)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -33.29

                    (-)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • -

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -19.28M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -12.63
                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  -

                  Style

                  -

                  Versartis Inc a development stage company was incorporated on December 10, 2008 in the State of Delaware. The Company is a biopharmaceutical company developing therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing novel drug candidates that it has licensed from Amunix Inc. The Company is engaged in developing its novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, and orphan disease. The Company faces competition from pharmaceutical, specialty pharmaceutical and biotechnology companies, generic drug companies, academic institutions and governmental agencies and public and private research institutions.

                  Key People

                  Jeffrey L. Cleland

                  CEO/Co-Founder/Director/President

                  Jay P. Shepard

                  Director/Chairman of the Board

                  Mr. Joshua T. Brumm

                  CFO

                  Dr. Srinivas Akkaraju,M.D.

                  Director

                  Edmon R. Jennings

                  Director

                  • Versartis Inc

                  • 275 Shoreline Drive

                  • Redwood City, CA 94065

                  • USA.Map

                  • Phone: +1 650 963-8580

                  • Fax: -

                  • versartis.com

                  Incorporated

                  2008

                  Employees

                  21